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Figure 2. FLT medullary uptake during myeloablation and marrow
repopulation
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S320prospectively enrolled on NCT01338987, who underwent
myeloablative HSCT for leukemia. Images analyzed included:
1) after ablation (day-1) evaluating for residual hematopoi-
esis, 2) early engraftment after HSCT (day +5-12), and 3) 28
days after HSCT, full marrow reconstitution. The algorithm
sensitively excluded uptake from non-marrow sources by
means of a CT mask that identiﬁed bone structures and
measured the total functional volume within the axial skel-
eton (Figure 1). Spinal and pelvic medullary volumes from CT
mask were median of 586.6 mL (range 400.9- 808.2 mL) and
a median of 860.2 mL (range 592.8-1054.1ml) respectively.
As expected, CT generated volume correlated signiﬁcantly
with height (cm) in spine (p¼.0002, R2¼0.62) and pelvis
(p¼.0125, R2¼0.37), and ideal body weight (kg) in spine
(p<.0001, R2¼0.74) and pelvis (p¼.0012, R2¼0.54). SUV
ranged from 0.6 to 4; marrowactivity was deﬁned> than 1.2,
per published literature. All patients were neutropenic
following HSCT, engrafted in the expected time frame, and
showed full donor chimerism. After myeloablation in the 14
non-relapse patients, less than 2% of the axial skeleton
demonstrated activity (range <1%-13%). By day 5-6 after
HSCT, this increased 8-fold to 17%(range 1%-28%), and it
increased by 36-fold by day 9-12 to 72%(range 56%-89%).
After 28 days, repopulated marrow showed proliferative
activity of 96% (81-99%) (p<0.02 between all 4 time points).
In summary, using a semi-automated analysis of 18FLT up-
take, we show that hematopoiesis of entire axial skeleton
with a single image, which also correlates with height and
ideal body weight, suggesting that this is an accurate and
sensitive assessment of the medullary space. Further, we
show that imaging may assess the degree of myeloablation
after HSCT, and that SUV can describe the degree of marrow
engraftment. Our data show that 18FLT could reveal failure of
myeloablation and engraftment failure within 5-6 days of
HSCT, which could be used to direct novel therapies and
improve outcomes.463
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The beneﬁcial application of regulatory T cells (Treg:
CD4+CD25+FoxP3+) for suppression of GVHD following allo-
geneic HSCTcontinues to evolve. Because of the challenges to
expand large numbers of these cells ex-vivo prior to trans-
plant, strategies to manipulate the compartment in situ
would represent a signiﬁcant advance for therapeutic
application in patients. Several cell surface molecules have
been identiﬁed as targets for expanding Treg cells in vivo.
Here we describe a new approach to regulate GVHD by
manipulating Tregs ﬁrst in the donor and subsequently in
recipients post-HSCT via targeting two signaling pathways,
IL2-CD25 and TL1A-TNFRSF25.
First, we compared different protocols involving simul-
taneous and non-overlapping schedules by infusing IL-2
either free or complexed with anti-JES6mAb (IAC) and a
TL1A-Ig fusion protein (FP) into normal B6-FoxP3RFP mice.
A highly reproducible protocol was developed, wherein FP
was administered ﬁrst, followed by IAC. This routinely
resulted in w50% FoxP3+/CD4+ T cells, and also an overall
increase in the CD4/CD8 ratio in these animals versus
controls (3.7 vs. 1.5 in lymph node and 4.1 vs. 1.7 in splenic
T cells). Notably, expanded Tregs exhibited elevated CD25
expression and there was a 4-5x increase in the KLRG1+
fraction of FoxP3+CD4+ T cells. The expanded Treg popula-
tion in these mice diminished by 50% in the ﬁrst 4 days
following cessation of treatment and returned to normal
levels within 2 weeks. We then examined transplant
outcome after obtaining cells from these Treg expanded
mice as donors for an allogeneic, complete MHC-mis-
matched HSCT. Lymph node cells from Treg-expanded B6-
FoxP3RFP (H2b) mice were transplanted together with
normal TCD-BM into lethally conditioned BALB/c (H2d)
recipients. Recipients were treated with different regimens
of TL1A-Ig and/or free IL-2 (10,000 units/mouse) early
post-HSCT. Mice were monitored for weight change, clin-
ical score and survival. Treg frequencies were determined
in the blood and tissues 1 week post-HSCT. Initial TL1A-Ig
treatment of recipients following transplant with Treg
expanded donor T cells resulted in rapid lethality. These
observations were consistent with the known effector cell
co-stimulation via TNFRSF25 in the presence of antigen.
Only Treg expansion in the donor combined with initial IL-
2 followed by TL1A-Ig treatment of the recipient post-HSCT
resulted in amelioration of GVHD. In summary, a combi-
nation strategy employing the targeted signaling of CD25
and TNFRSF25 was identiﬁed which can markedly expand
Treg cells including a KLRG1+ population. Signaling via
TNFRSF25 followed by CD25 in T cell donors in conjunction
with the reverse targeting of these receptors in recipients
post-transplant resulted in attenuation of GVHD.464
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